Clinical trial
Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an…
NCT00111085 · Idorsia Pharmaceuticals Ltd., Industry · Completed
Key facts
| NCT number | NCT00111085 |
|---|---|
| Title | Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH) |
| Official title | A Phase IIb, Multi-center, International, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding Study for the Prevention of Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage (aSAH) by Intravenous Administration of Clazosentan, a Selective Endothelin A (ETA) Receptor… |
| Acronym | CONSCIOUS-1 |
| Lead sponsor | Idorsia Pharmaceuticals Ltd., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Aneurysmal Subarachnoid Hemorrhage |
| Intervention type | Drug |
| Interventions | Clazosentan 1 mg/h, Clazosentan 5 mg/h, Clazosentan 15 mg/h, Placebo |
| Enrollment | 413 |
| Start date | Jan 10, 2005 |
| Primary completion | Mar 30, 2006 |
| Completion | Mar 30, 2006 |
| First posted | May 18, 2005 |
| Last update posted | Jul 10, 2018 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: